ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoclasts and rheumatoid arthritis (RA)"

  • Abstract Number: 1824 • 2018 ACR/ARHP Annual Meeting

    Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss

    Olivier Peyruchaud1, Sacha Flammier1, Fanny Bourguillault1, Francois Duboeuf1, Gabor Tigyi2, Irma Machuca-Gayet1 and Fabienne Coury1, 1INSERM UMR1033, Lyon, France, 2Department of Physiology, University of Tennessee, Memphis, TN

    Background/Purpose: Rheumatoid arthritis (RA) patients in sustained clinical remission or low disease activity may continue to accrue periarticular bone erosions despite control of inflammation. Osteoclasts…
  • Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting

    Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells

    Pooja Naik1, Jing Shi2, Felipe Andrade3 and Erika Darrah4, 1Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
  • Abstract Number: 53 • 2017 ACR/ARHP Annual Meeting

    Poly-γ-Glutamic Acid Inhibits RANKL- Induced Osteoclast Differentiation and Prevents Bone Destruction in Rheumatoid Arthritis: Human and CIA Mouse Model

    Bitnara Lee1, Jong-Dae Ji2 and Tae-Hwan Kim1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Rheumatology, Korea University Hospital, Seoul, Korea, Republic of (South)

    Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disease that is characterized by chronic inflammation and bone destruction. Osteoclasts, which are bone-resorbing cells, are generally known…
  • Abstract Number: 1944 • 2017 ACR/ARHP Annual Meeting

    A Dual Role for IL-23 Receptor Signaling in Normal Bone Remodeling Versus Inflammation-Mediated Bone Damage during Arthritis

    Wida Razawy1, Marijke Koedam2, Patrick Asmawidjaja3, Anne-Marie Otten-Mus4, Bram van der Eerden2 and Erik Lubberts3, 1Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, 2Internal Medicine, Erasmus MC, Rotterdam, Netherlands, 3Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

    Background/Purpose: The interleukin (IL)-23/IL-17A immune pathway is critical for the development of autoimmune arthritis. Systemic exposure of IL-23 induced chronic arthritis, increased osteoclast differentiation and…
  • Abstract Number: 580 • 2016 ACR/ARHP Annual Meeting

    Preferential Distribution of M1 Monocytes in Anti-Cyclic Citrullinated Peptide Antibody Positive Patients with Rheumatoid Arthritis

    Shoichi Fukui1, Naoki Iwamoto2, Toshimasa Shimizu2, Masataka Umeda2, Ayako Nishino3, Yoshiro Horai2, Tomohiro Koga4, Shin-ya Kawashiri5, Kunihiro Ichinose6, Yasuko Hirai2, Mami Tamai6, Hideki Nakamura5, Tomoki Origuchi7 and Atsushi Kawakami4, 1Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, 4Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan

    Background/Purpose: In rheumatoid arthritis (RA), bone erosions are caused mainly by osteoclasts. Osteoclasts are derived from monocytes and macrophages (MoMa). MoMa consists of different subtypes…
  • Abstract Number: 1449 • 2016 ACR/ARHP Annual Meeting

    The Efficiency of the Regulation of Ca2+ Entry through Calcium Release-Activated Calcium Channel in the Treatment of Rheumatoid Arthritis

    Shuang Liu1, Hitoshi Hasegawa2, Takeshi Kiyoi3, Tatsuya Sawasaki4 and Kazutaka Maeyama5, 1Dept. Pharmacology,, Ehime University Graduate School of Medicine, Toon-shi, Japan, 2Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan, 3Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, 4Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Japan, 5Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan

    Background/Purpose:  The regulation of Ca2+ entry by targeting a store-operated calcium release-activated channel (CRAC), known as ORAI, has shown benefits in the treatment of rheumatoid…
  • Abstract Number: 1156 • 2015 ACR/ARHP Annual Meeting

    Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis

    MIN-YOUNG JUNG1, Hae-Rim Kim2, HYUN-SOOK KIM3, HO-YOUN KIM1 and Sang Heon Lee4, 1Konkuk university hospital, Seoul, South Korea, 2Division of Rheumatology, Konkuk University School of Medicine, Seoul, South Korea, 3Soonchenhyang university school of medicine, Seoul, South Korea, 4Konkuk University Hospital, Seoul, South Korea

    Background/Purpose: This study aimed to determine the regulatory effect of Th17 cytokines on osteoclastogenesis in rheumatoid arthritis (RA). Methods: The expression of interleukin (IL)-17 and…
  • Abstract Number: 2707 • 2015 ACR/ARHP Annual Meeting

    An in Vitro Bovine Bone Chip Model with Micro-CT: A Model for the Assessment of Autoantibody Mediated Bone Resorption

    Manpreet Kaur Sethi1, Anand Dusad1, Andy Hollins2, Carlos D. Hunter3, Michael J. Duryee3, Ted R. Mikuls2, Geoffrey M. Thiele4 and Ellen M. Gravallese5, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are specific to rheumatoid arthritis (RA) and are associated with disease severity.  Although ACPAs are associated with disease progression, mechanisms…
  • Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting

    A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results

    Lei Zhou1, Robert Sikorski1, Seema Rogers1, Stefan Costin2, Mariusz Korkosz3, Maria Jaraczewska-Baumann4, Péterfai Éva5, Bernadette Rojkovich6, Janos Bartalos7, Emma Masteller1, Hong Xiang1, Brian Wong1 and Julie Hambleton1, 1Five Prime Therapeutics, Inc., South San Francisco, CA, 2PRA Heath Sciences, Berlin, Germany, 3Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, 4MedPolonia Sp. z o.o, Poznan, Poland, 5Drug Research Center, Balatonfüred, Hungary, 6Hospitaller Brothers of St. John of God, Budapest, Hungary, 7PRA Hungary Ltd, Budapest, Hungary

    Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
  • Abstract Number: 2820 • 2014 ACR/ARHP Annual Meeting

    Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation

    Nida Meednu1, Hengwei Zhang2, Teresa Owen3, Lianping Xing4 and Jennifer H. Anolik5, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, 3Rheumatology, University of Rochester, Rochester, NY, 4Pathology & Lab Medicine, University of Rochester, Rochester, NY, 5Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…
  • Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting

    Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

    Anita Boyapati1, Jérôme Msihid2, Emmanuelle Cousin3, Ling Cai4, Janet van Adelsberg1, Jennifer D Hamilton1, Neil Graham5, Tanya Momtahen6 and Stefano Fiore7, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi R&D, France, Chilly-Mazarin, NJ, France, 3Sanofi R&D, France, Chilly-Mazarin, France, 4Sanofi R&D, China, Beijing, China, 5Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Sanofi, Bridgewater, NJ, 7Distinct Project Unit, Sanofi, Bridgewater, NJ

    Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
  • Abstract Number: 323 • 2014 ACR/ARHP Annual Meeting

    Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation

    Yen-You Lin1, Hsin-Pai Lee1,2, Shi-Ying Huang1, Han-Chun Hung3, Chien-Wei Feng3, Chun-Hong Chen3, Jui-Hsin Su4,5, Ping-Jyun Sung4,5, Jyh-Horng Sheu1,3, Yen-Hsuan Jean2 and Zhi-Hong Wen1,3, 1Department of Marine Biotechnology and Resources, Asia-Pacific Ocean Research Center, National Sun Yat-Sen University, Kaohsiung, Taiwan, 2Section of Orthopedic Surgery, Pingtung Christian Hospital, Pingtung, Taiwan, 3Doctoral Degree Program in Marine Biotechnology, National Sun Yat-Sen University, Kaohsiung, Taiwan, 4Graduate Institute of Marine Biotechnology, National Dong Hwa University, Pingtung, Taiwan, 5Taiwan Coral Research Center, National Museum of Marine Biology & Aquarium, Pingtung, Taiwan

    Background/Purpose: Osteoclasts are multinucleated giant cells of macrophage/monocyte lineage, and are believed to play major roles in joint destruction caused by rheumatoid arthritis (RA). Nuclear…
  • Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting

    Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Naoki Ishiguro3, Hisashi Yamanaka4, Toshiyuki Yoneda5, Harry K. Genant6 and Désiréé van der Heijde7, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Keio University, Tokyo, Japan, 3Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Indiana University School of Medicine, Indianapolis, IN, 6University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, 7Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…
  • Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting

    Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts

    Sandra Mueller-Schmucker1, Roland Axmann1, Sonja Herman2, Mario Zaiss1, Manuela Le Bars3, Thomas Harrer1 and Georg A. Schett4, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…
  • Abstract Number: 329 • 2012 ACR/ARHP Annual Meeting

    The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen-Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines

    Polly Pine1, Ayodele Apatira1, Betty Y. Chang1, Nathan Schoettler2, Elliott B. Grossbard3 and Ernest Brahn2, 1Pharmacology, Rigel Pharmaceuticals, So San Francisco, CA, 2Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3Rigel Pharmaceuticals, So San Francisco, CA

    Background/Purpose: Spleen tyrosine kinase (SYK) is expressed in hematopoietic cells and is a major downstream regulator of signaling through Fcγ and immunoglobulin receptors as well…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology